Oncology Based In-Vivo CRO

Oncology Based In-Vivo CRO

Global Oncology Based In-Vivo CRO Market to Reach US$2.5 Billion by 2030

The global market for Oncology Based In-Vivo CRO estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2023-2030. Solid Tumors Indication, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Blood Cancer Indication segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$421.9 Million While China is Forecast to Grow at 6.5% CAGR

The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$421.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$383.5 Million by the year 2030 trailing a CAGR of 6.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.7% CAGR.

Global Oncology Based In-Vivo CRO Market - Key Trends and Drivers Summarized

How Is Oncology Based In-Vivo CRO Supporting Cancer Research?

Oncology-based In-Vivo Contract Research Organizations (CROs) provide specialized services for preclinical testing of cancer therapies in live animal models. These CROs offer comprehensive in-vivo studies, including pharmacology, toxicology, and efficacy assessments, enabling pharmaceutical and biotech companies to evaluate the potential of new cancer drugs before clinical trials. By utilizing animal models that mimic human cancer conditions, CROs help researchers understand drug behavior, dosage optimization, and side effects. The growing complexity of cancer treatments, which now include immunotherapies, targeted therapies, and gene therapies, has increased the demand for specialized in-vivo studies to ensure safety and efficacy.

What Are the Key Segments in the Oncology Based In-Vivo CRO Market?

Key services include pharmacokinetics (PK), pharmacodynamics (PD), toxicology, and efficacy testing, with pharmacokinetics and pharmacodynamics being the most in-demand services due to their importance in early-stage drug development. The application segment covers different cancer types, such as lung cancer, breast cancer, colorectal cancer, and blood cancers, with lung and breast cancer studies accounting for a significant share due to their high prevalence and active drug development pipelines. Major end-users include pharmaceutical companies, biotechnology firms, and academic research institutions, all of which rely on in-vivo CROs to advance their oncology drug discovery efforts.

How Are In-Vivo CROs Integrated Into Oncology Research?

Pharmaceutical companies collaborate with in-vivo CROs to conduct preclinical testing for new cancer treatments, reducing the time and cost associated with drug development. These CROs offer tailored in-vivo models, including patient-derived xenografts (PDX), syngeneic models, and transgenic models, to accurately represent human tumor biology. Biotechnology firms, often focusing on novel therapies like CAR-T cells and bispecific antibodies, use in-vivo CROs for efficacy and safety evaluations before moving to clinical trials. Academic and research institutions also work with CROs to study the mechanisms of action of potential cancer therapies and identify promising drug candidates. The integration of advanced technologies, such as imaging tools and biomarker analysis, has enhanced the accuracy and relevance of in-vivo studies in oncology research.

What Factors Are Driving the Growth in the Oncology Based In-Vivo CRO Market?

The growth in the Oncology Based In-Vivo CRO market is driven by several factors, including the increasing prevalence of cancer, which has fueled demand for new therapies and accelerated drug development. The shift toward targeted and personalized treatments, such as immunotherapies and gene therapies, has necessitated the use of specialized in-vivo models that accurately mimic human tumors. Advancements in preclinical research tools, such as imaging techniques and biomarker analysis, have improved study accuracy and efficiency, supporting broader adoption. The rise in collaborations between CROs and biopharma companies, along with increased government funding for cancer research, has further contributed to market growth. Additionally, the growing number of biotech startups focused on innovative oncology therapies has boosted demand for in-vivo CRO services.

Select Competitors (Total 42 Featured) -
  • Champion Oncology, Inc.
  • Charles River Laboratory
  • Covance
  • Crown Bioscience
  • Eurofins Scientific
  • EVOTEC
  • ICON Plc
  • Living Tumor Laboratory
  • MI Bioresearch, Inc.
  • Taconic Biosciences
  • The Jackson Laboratory
  • Wuxi AppTec
  • Xentech
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Oncology Based In-Vivo CRO – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Cancer Research Spurs Growth in Oncology-Based In-Vivo CRO Market
Technological Advancements in Preclinical Models and Imaging Strengthen Business Case for Adoption
Growing Focus on Personalized Medicine and Immuno-Oncology Expands Addressable Market
Expansion of In-Vivo CROs in Drug Discovery, Translational Research, and Toxicology Fuels Market Growth
Increasing Adoption of In-Vivo Models in Target Validation, Biomarker Identification, and Efficacy Studies Expands Market Opportunities
Technological Innovations in Animal Models, Xenografts, and Patient-Derived Tumor Models Propel Market Expansion
Growing Use of In-Vivo CROs in Cell Therapy, Gene Therapy, and Antibody-Drug Conjugates (ADCs) Expands Market Potential
Focus on Achieving Faster Time-to-Market for New Therapies Strengthens Market for Oncology-Based In-Vivo CRO
Technological Advancements in High-Throughput Screening, Genomics, and Imaging Propel Market Growth
Increasing Focus on Integrating In-Vivo CROs with Big Data Analytics and Real-Time Monitoring Drives Adoption
Rising Demand for In-Vivo CRO Services in Immuno-Oncology, Radiotherapy, and CAR-T Therapy Strengthens Global Market
Expansion of Oncology-Based In-Vivo CROs in Rare Cancers, Pediatric Oncology, and Early-Phase Trials Expands Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Oncology Based In-Vivo CRO Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 14: USA Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 15: USA Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: USA 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
CANADA
TABLE 17: Canada Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 18: Canada Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: Canada 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
JAPAN
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 20: Japan Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: Japan Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: Japan 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
CHINA
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 23: China Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: China Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: China 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
EUROPE
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 26: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: Europe Historic Review for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 29: Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
FRANCE
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 32: France Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: France Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: France 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
GERMANY
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 35: Germany Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Germany Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Germany 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
ITALY
TABLE 38: Italy Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Italy Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Italy 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
UNITED KINGDOM
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 41: UK Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: UK Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: UK 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Rest of Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Rest of Europe 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: Asia-Pacific Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: Asia-Pacific 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 50: Rest of World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Rest of World Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Rest of World 16-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings